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INTRODUCTION 
 2
Diabetes mellitus is a group of metabolic disorders with one 
common manifestation: hyperglycemia. Type 1 diabetes mellitus 
(formerly called type I, IDDM or juvenile diabetes) is characterized by 
beta cell destruction caused by an autoimmune process, usually leading to 
absolute insulin deficiency1. Over 95 percent of persons with type 1 
diabetes mellitus develop the disease before the age of 25. Most of these 
patients have the "immune-mediated form" of type 1 diabetes mellitus 
with islet cell antibodies and often have other autoimmune disorders.1 
The Metabolic Syndrome also called Insulin Resistance Syndrome 
or syndrome X, is a cluster of metabolically related cardiovascular risk 
factors, the core components of which comprise of central obesity, insulin 
resistance, dyslipidemia, and hypertension.2 The presence of the 
metabolic syndrome predicts the risk of cardiovascular disease in 
nondiabetic subjects as well as in those with diabetes.3 There are multiple 
definitions for the metabolic syndrome, with one of the recent ones being 
the consensus from the National Cholesterol Education Programme –
NCEP ATP III Criteria.  
A report from the National Cholesterol Education Program- Adult 
Treatment Panel (NCEP-ATP III) identified metabolic syndrome as an 
independent risk factor for cardiovascular disease and considered it an 
indication for intensive lifestyle modification. Metabolic syndrome is 
associated with a proinflammatory/prothrombotic state that may include 
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elevated levels of C-reactive protein, endothelial dysfunction, 
hyperfibrinogenemia, increased platelet aggregation, increased levels of 
plasminogen activator inhibitor 1, elevated uric acid levels, 
microalbuminuria, and a shift toward small, dense particles of low-
density lipoprotein (LDL) cholesterol. 
Central to the development of the metabolic syndrome appears to 
be the presence of increased insulin resistance. Although this is a 
characteristic usually associated with the development of type 2 diabetes, 
it can also be a feature of patients with type 1 diabetes.4 When present in 
type 1 diabetes, the phrase "double diabetes" has been coined, with the 
assumption that these patients are likely to be at especially high risk of 
developing cardiovascular disease.5  
The etiology of the metabolic syndrome has not been established 
definitively. One hypothesis presumes that the primary cause is insulin 
resistance. Insulin resistance correlates with visceral fat measured by 
waist circumference or waist to hip ratio. The link between insulin 
resistance and cardiovascular disease probably is mediated by oxidative 
stress, which produces endothelial cell dysfunction, promoting vascular 
damage and atheroma formation. 
The second hypothesis blames hormonal changes for the 
development of abdominal obesity. One study demonstrated that persons 
with elevated levels of serum cortisol (caused by chronic stress) 
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developed abdominal obesity, insulin resistance, and lipid abnormalities. 
The investigators concluded that this inappropriate activation of the 
hypothalamic-pituitary-adrenal axis by stress is responsible for the link 
between psychosocial and economic problems, and acute myocardial 
infarction. 
Diabetes in most cases is caused by a loss of the physical or 
functional ß-cell mass, mostly due to an autoimmune process (type 1 
etiological process) and/or increased need for insulin due to insulin 
resistance (type 2 process) . Both of these major diabetes types are 
believed to include different stages of disease, ranging from non–insulin-
requiring to insulin-requiring for control or survival. According to this 
classification adopted by the World Health Organization, it is quite 
possible that both processes would operate in a single patient and 
contribute to the phenotype of the patient. Also, factors other than 
autoimmunity can lead to a defective insulin response to glucose. Both 
major diabetes types are considered multifactorial diseases with several 
predisposing genetic and environmental factors, some of which could be 
common to both types. In populations with a high prevalence of type 1 
diabetes, like in Finland, a large proportion of patients with type 2 
diabetes should have inherited susceptibility genes for both types of 
diabetes. Also, the lifestyle changes leading to the type 2 diabetes 
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epidemic around the world may have an impact on the clinical picture of 
type 1 diabetes in the subjects at risk for type 2 diabetes as well.  
The metabolic syndrome has been shown to confer an increased 
risk of cardiovascular disease in both the general and type 2 diabetic 
populations, but few studies have assessed the metabolic syndrome in 
type 1 diabetic patients. In a type 1 diabetic cohort, we assessed the 
prevalence of metabolic syndrome and tried to identify risk factors which 
predispose individuals to develop this constellation of findings.  
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REVIEW OF LITERATURE 
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The Metabolic Syndrome  
              Abnormalities in glucose and lipid metabolism, obesity, and high 
blood pressure occur together commonly enough in the same individuals 
as to suggest that they are somehow interrelated. In fact, this cluster of 
abnormalities has come to be known as a syndrome, going by a variety of 
names, including Syndrome X, the Deadly Quartet, and the Insulin 
Resistance Syndrome.  
Metabolic syndrome was initially observed in 1923 by Kyln, who 
described the clustering of hypertension, hyperglycemia and gout as the 
syndrome. Reaven6 first described syndrome X to comprise of central 
obesity, hyperinsulinemia, hyperuricemia, hypertriglyceridemia, and a 
propensity to coronary heart disease (CHD) and stroke. The insulin 
resistance syndrome (IRS) has since been expanded from this core 
phenotype to become increasingly recognized by physicians.  
In 2001 NCEP ATP III formulated criteria to diagnose Metabolic 
Syndrome. IDF( International Diabetes Federation) has recently , in 2005, 
announced its own set of criteria which are slightly different from the 
NCEP criteria. 
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Aetiopathogenesis 
  The mechanisms underlying the metabolic syndrome are not fully 
known; however resistance to insulin stimulated glucose uptake seems to 
modify biochemical responses in a way that predisposes to metabolic risk 
factors.7 A central role has been attributed to the pro-inflammatory 
cytokines, tumor necrosis factor a (TNF- a) and interleukin (IL)-6, 
supported by the fact that both are produced in substantial amounts by 
human adipose tissue. TNF-a impairs insulin-stimulated glucose uptake 
in a variety of cells and decreases lipoprotein lipase activity. Both 
cytokines increase hepatic lipogensis and elicit a systemic acute- phase 
response.8 
Furthermore, various aspects of the acute-phase response, such as 
fibrinogen and plasminogen activator inhibitor-1 levels, whole-blood 
viscosity, and white blood cell count, have recently been found to 
correlate positively with the metabolic syndrome.9 This is of particular 
interest because inflammation plays an important role in the pathogenesis 
of atherothrombosis. 
Macrophage and T-cell infiltration is a major feature of 
atherosclerotic plaques, especially at sites of plaque rupture, and 
epidemiological studies show strong positive associations of systemic 
markers of inflammation with atherothrombotic disease.10 
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Moreover, C-reactive protein (CRP), the classic and exquisitely 
sensitive acute phase reactant, shows a strong independent association 
with the risk of Coronary Heart Disease and other atherothrombotic 
events. CRP levels have also been found to correlate with BMI and some 
features of the metabolic syndrome. 
The AHA/NHLBI/ADA conference identified three potential 
etiologic categories: 
1. Obesity and disorders of adipose tissue. 
2. Insulin resistance. 
3. A constellation of independent risk factors (e.g. molecules of hepatic, 
vascular and immunologic origin) that mediate specific component of 
syndrome like hypertension,  
              prothrombotic state,  
              lipoprotein metabolic ageing  
              and physical inactivity.  
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Figure 1 Shows the interaction among the various risk factors of 
cardiovascular disease. 
Cardiovascular risk and Metabolic Syndrome: 
The importance of the Metabolic syndrome lies in its 
consequences. The syndrome is typically characterized by varying 
degrees of glucose intolerance, abnormal cholesterol and/or triglyceride 
levels, high blood pressure, and central obesity, all independent risk 
factors for cardiac disease. If one includes along with the classic four 
features the commonly associated conditions of aging, sedentary lifestyle, 
stress, smoking, and a dose of genetic susceptibility, then a deadly web of 
increased cardiovascular disease risk is woven. In fact, the presence of 
any one major feature alone substantially increases the risk of heart 
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disease, but when they occur together the risk is magnified way out of 
proportion at the contribution of any one single factor.  
This point was strikingly demonstrated by the PROCAM 
(Prospective Cardiovascular Munster) 11 Study, in which the relationship 
between various cardiac risk factors and the incidence of heart attack over 
a four year period was examined in 2,754 men aged 40-65 years. The 
results showed that the presence of diabetes or high blood pressure alone 
increased the risk of heart attack by 2.5 times. When both diabetes and 
high blood pressure were present, the risk was increased 8 times. An 
abnormal lipid profile increased the risk 16 times; when abnormal lipid 
levels were present with high blood pressure and/or diabetes, the risk was 
20 times higher.  
        Hanna-Maaria Lakka, David E. Laaksonen,et al conducted a study in 
Finland to assess the association of the metabolic syndrome with 
cardiovascular and overall mortality. The Kuopio Ischaemic Heart 
Disease Risk Factor Study, a population-based, prospective cohort study 
of 1209 Finnish men aged 42 to 60 years at baseline (1984-1989) who 
were initially without CVD, cancer, or diabetes, was used for the study. 
The results conclusively showed that cardiovascular disease and all-cause 
mortality are increased in men with the metabolic syndrome, even in the 
absence of baseline CVD and diabetes.12 
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Christoph H. Saely, Stefan Aczel et al studies the impact of the MetS 
(Adult Treatment Panel III criteria) and insulin resistance (as estimated 
by the homeostasis model assessment index) on the incidence of vascular 
events. It was a prospective cohort study enrolling 750 consecutive 
patients undergoing coronary angiography for the evaluation of coronary 
artery disease at a tertiary care clinical research center. The main outcome 
measured was the incidence of vascular events over 2.3 yr. And they 
concluded that both the Metabolic syndrome and insulin resistance were 
strong and mutually independent predictors of vascular risk among 
angiographed coronary patients.13 
Metabolic syndrome and Type 2 Diabetes: 
Bo Isomaa, Peter Almgren, Tiinamaija Tuomi et al conducted a study 
to find out the prevalence of and the cardiovascular risk associated with 
the metabolic syndrome using the new definition proposed by the World 
Health Organization (WHO). A total of 4,483 subjects aged 35–70 years 
participating in a large family study of type 2 diabetes in Finland and 
Sweden (the Botnia study) were included. Cardiovascular mortality was 
assessed in 3,606 subjects with a median follow-up of 6.9 years. In 
women and men, respectively, the metabolic syndrome was seen in 10 
and 15% of subjects with NGT, 42 and 64% of those with IFG/IGT, and 
78 and 84% of those with type 2 diabetes.  
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The risk for coronary heart disease and stroke was increased threefold 
in subjects with the syndrome (P < 0.001). Cardiovascular mortality was 
markedly increased in subjects with the metabolic syndrome (12.0 vs. 
2.2%, P < 0.001). Of the individual components of the metabolic 
syndrome, microalbuminuria conferred the strongest risk of 
cardiovascular death (RR 2.80; P = 0.002).Their study results clearly 
showed that the WHO definition of the metabolic syndrome identifies 
subjects with increased cardiovascular morbidity and mortality and offers 
a tool for comparison of results from different studies.14  
From the above studies quoted an association between type 2 DM, 
Metabolic Syndrome and Cardiovascular risk have been shown to be 
clearly established. 
Type 1 Diabetes Mellitus: 
Type 1 diabetes is an autoimmune disease that results in the 
permanent destruction of insulin producing beta cells of the pancreas. 
This etiology makes type 1 distinct from type 2 diabetes mellitus. Type 1 
is lethal unless treatment with exogenous insulin via injections replaces 
the missing hormone. 
Chronic complications of Type 1 Diabetes are similar to those seen 
in Type 2 DM. The vascular complications are divided into microvascular 
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(retinopathy, neuropathy, nephropathy) and macrovascular (coronary 
artery disease, cerebrovascular disease, peripheral vascular disease). 
The DCCT, UKPDS and Kumamoto study support the idea that 
chronic hyperglycemia plays a causative role in the pathogenesis of 
diabetic microvascular complications but evidence implicating a 
causative role for the same in the development of macrovascular 
complications is less conclusive .15 Intensive Insulin therapy has been 
shown to effectively delays the onset and slow the progression of diabetic 
retinopathy, nephropathy, and neuropathy in patients with IDDM.16 A 
study on the Effect of intensive diabetes management on macrovascular 
events and risk factors in the Diabetes Control and Complications Trial 
showed that intensive insulin therapy showed a reduction in some but not 
all cardiovascular risk factors in Type 1 DM.17  
 Other factors like dyslipidemia and hypertension play 
important roles in macrovascular complications. 10-year follow-up data 
from the Pittsburgh Epidemiology of Diabetes Complications study 
showed that Insulin Resistance–Related Factors, but not Glycemia, 
Predict Coronary Artery Disease in Type 1 Diabetes.18 So the presence of 
metabolic syndrome will considerably increase the risk of cardiovascular 
adverse events in patients with Type 1 DM. 
Both the microvascular and macrovascular complications translate 
directly into increased morbidity and mortality among these young 
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patients with Type 1 DM. A follow-up study of 1966 patients with 
insulin-dependent diabetes mellitus (IDDM) who were diagnosed at 
Children's Hospital of Pittsburgh (CHP) between 1950 and 1981 showed 
a sevenfold excess in mortality compared with the U.S. population. After 
age 20, the annual mortality risk was approximately 2%, which was more 
than 20 times greater than for the U.S. population.19 
Sabita S. Soedamah-Muthu, John H. Fuller, et al estimated the Risk 
of Cardiovascular Disease in Patients With Type 1 Diabetes in the U.K. 
Subjects with type 1 diabetes (n = 7,479) and five age- and sex-matched 
subjects without diabetes (n = 38,116) and free of CVD at baseline were 
selected from the General Practice Research Database (GPRD), a large 
primary care database representative of the U.K. population. Incident 
major CVD events, comprising myocardial infarction, acute coronary 
heart disease death, coronary revascularizations, or stroke, were captured 
for the period 1992–1999. This data showed that absolute and relative 
risks of CVD remain extremely high in patients with type 1 diabetes. 
Women with type 1 diabetes continue to experience greater relative risks 
of CVD than men compared with those without diabetes.20 
The risk of mortality from ischemic heart disease is exceptionally 
high in young adult women with Type 1 diabetes, with rates similar to 
those in men with Type 1 diabetes under the age of 40. These 
observations emphasize the need to identify and treat coronary risk 
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factors in these young patients. These conclusions were drawn in a study 
on ‘Mortality from heart disease in a cohort of 23,000 patients with 
insulin-treated diabetes.’ Conducted using the database of ‘Diabetes UK 
cohort’.21 
Magnitude of the problem: 
Type 1 Diabetes is a relatively rare disease. The prevalence of type 
1 diabetes mellitus in India is 10.1-10.6 per hundred thousand.22 The 
crude prevalence rate of diabetes in urban areas is about 9% and that the 
prevalence in rural areas has also increased to around 3% of the total 
population. The type of diabetes which we see in India is considerably 
different from that described in the western literature. Although the 
estimate of Type 1 is around 1% of the total diabetics, the vast majority 
of the so-called Type 1 differ significantly from their western 
counterparts.  
Metabolic syndrome is a very commonly found condition in the 
Indian adult population especially among patients with Type 2 DM. 
Metabolic syndrome is highly prevalent among urban Indians (41.1 %). 
Its prevalence increased with age and was higher among women.23 Age 
wise prevalence for metabolic syndrome is not available. 
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Table 1 Showing prevalence of metabolic syndrome in India by 
various studies. Adapted from Misra A , Met Syndrome and related 
disorders, 2004. 
 
Author, Year, City. 
           PREVALENCE 
     O     M      F 
Kasliwal et al, 2005, Delhi 28.5 - - 
Gupta et al, 2004, Jaipur 25 18 31 
Misra et al, 2004, Delhi 12 8 15 
Gupta et al, 2003, Jaipur 13 10 20 
Ramachandran et al , 2003, Chennai 41 - - 
     
The prevalence of Metabolic syndrome among Type 1 diabetics 
has been described to vary from 17% to 40% by various studies.24-25 No 
data was found describing the occurrence of this complication among 
Indian patients with Type 1 DM, which is the aim of this study. 
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Identification of Metabolic Syndrome. 
Various criteria are in current clinical practice to identify patients 
with Metabolic syndrome. The more commonly used ones are WHO 
criteria, NCEP ATP III criteria and IDF criteria. 
WHO was the first to publish internationally accepted criteria for 
Metabolic Syndrome in 1998.The WHO criteria are as follows: 
1. High insulin levels, an elevated fasting blood glucose or an 
elevated post meal glucose alone with at least 2 of the following 
criteria:  
 Abdominal obesity as defined by a waist to hip ratio of 
greater than 0.9, a body mass index of at least 30 kg/m2 or a 
waist measurement over 37 inches.  
2. Cholesterol panel showing a triglyceride level of at least 150 
mg/dl or an HDL cholesterol lower than 35 mg/dl.  
3. Blood pressure of 140/90 or above (or on treatment for high blood 
pressure).  
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But the criteria that have received the most widespread acceptance and 
use are those proposed by NCEP ATP III. The criteria are : 
 Central/abdominal obesity as measured by waist circumference 
[Men - Greater than 40 inches (102 cm); Women - Greater than 35 
inches (88 cm)]  
  Fasting triglycerides greater than or equal to 150 mg/dL (1.69 
mmol/L)  
 HDL cholesterol [Men - Less than 40 mg/dL (1.04 mmol/L); 
Women - Less than 50 mg/ dL (1.29 mmol/L)]  
 Blood pressure greater than or equal to 130/85 mm Hg  
 Fasting glucose greater than or equal to 110 mg/dL (6.1 mmol/L). 
In this study we have used the NCEP ATP III as it is the one found to 
be most applicable in this setup. All the risk factors have been compiled 
based on the NCEP ATP III only. 
The IDF criteria is the most recent criteria and here abdominal 
obesity has been used as a mandatory requisite. According to the new 
IDF definition, for a person to be defined as having the metabolic 
syndrome they must have: 
 Central obesity (defined as waist circumference > 94cm for 
Europoid men and > 80cm for Europoid women, with ethnicity 
specific values for other groups) plus any two of the following four 
factors: 
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 raised TG level: > 150 mg/dL (1.7 mmol/L), or specific treatment 
for this lipid abnormality 
 reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L*) in males 
and < 50mg/dL (1.29 mmol/L*) in females, or specific treatment 
for this lipid abnormality 
 raised blood pressure: systolic BP 3 130 or diastolic BP 3 85 mm 
Hg, or treatment of previously diagnosed hypertension 
 raised fasting plasma glucose (FPG) > 100 mg/dL (5.6 mmol/L), or 
previously diagnosed type 2 diabetes. If above 5.6 mmol/L or 100 
mg/dL, OGTT is strongly recommended but is not necessary to 
define presence of the syndrome. 
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From the above discussion it is clear that Metabolic syndrome is 
achieving epidemic proportions in India. And with various studies clearly 
demonstrating an absolute increase in cardiovascular risk with the 
occurrence of this constellation of factors, occurrence of metabolic 
syndrome is turning out to be a harbinger of major complications. 
Type 1 DM though is a rare disease, is one that afflicts the young 
population of our country. These patients, if diagnosed early and 
managed effectively with insulin therapy and regular follow up to detect 
complications, can live a productive and fulfilling life.  
The concept of insulin resistance playing a role in the 
complications occurring in these insulin deficient patients is a relatively 
new one. But there are studies which have elegantly showed that the 
metabolic syndrome does occur in these patients thus multiplying their 
cardiovascular risk. But data on this subset of patients and what causes 
them to develop insulin resistance in the Indian scenario is sparse.  
So, this study has been undertaken to estimate the prevalence 
of Metabolic syndrome among patients with type 1 DM using the 
NCEP ATP III criteria. We have attempted to identify risk factors for 
the same.  
The results of this study will not only estimate the prevalence and 
risk factors but will be useful to understand better the pathophysiological 
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mechanisms underlying the Metabolic Syndrome not only in type 1 
diabetics but also in the general population and in those with Type 2 DM.  
Early identification of Metabolic syndrome in Type 1 diabetics can 
help to aggressively initiate lifestyle modifications and therapeutic 
interventions to decrease the morbidity and mortality associated with this 
disease. 
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AIMS AND OBJECTIVES 
1. To estimate the prevalence of Metabolic syndrome among patients 
with Type 1 Diabetes Mellitus. 
2. To identify the risk factors predisposing patients with type 1 DM to 
develop Metabolic Syndrome. 
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MATERIALS AND METHODS 
 
 Setting – Out Patient Department, Department of Diabetolgy, 
Government General Hospital, Madras Medical College, Chennai 
 
 Collaboration Departments- Department of Diabetology,  
Government General Hospital, Madras Medical College, Chennai 
 
 Ethical committee Approval- Obtained 
 
 Design of study- Descriptive Study 
 
 Period of study-  January 2006- June 2007  
 
 Sample size- 100 patients  
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Maneuver: 
The study was carried out in the out patient clinic of the 
Department of Diabetology. Type 1 Diabetes patients who were 
registered there were enrolled for the study after obtaining their consent. 
A total of 100 patients were selected as per the Inclusion and Exclusion 
criteria. 
Patient’s socio demographic data was recorded in the proforma 
sheet. The duration of their diabetes and the current insulin requirement 
per day were noted. Since HbA1c was not available the status of their 
glycaemic control was determined by taking an average of their monthly 
Fasting Blood Sugar values over a period of one year33. 
Physical measurements, with the participants in bare feet and in 
light clothing, included height measured to the nearest centimetre, and 
weight to the nearest 10th of a kilogram (1 kg was deducted from the 
weights recorded as an allowance for clothing). 
Waist circumference was measured around the narrowest point 
between ribs and hips when viewed from the front after exhaling. Hip 
circumference was measured at the point where the buttocks extended the 
maximum, when viewed from the side. Two consecutive recordings were 
made for each site to the nearest 1 cm using an inch tape on a horizontal 
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plane without compression of skin. The mean of two sets of values was 
used.  
Blood pressure levels were obtained using mercury 
sphygmomanometers on the right arm of seated subjects. Systolic and 
phase 4 diastolic pressures were taken twice to the nearest 2 mmHg and 
the average recorded. 
Fasting blood samples collected into heparinised tubes and sent to 
the Central Laboratory, Institute of Biochemistry, Madras Medical 
College. Plasma cholesterol and triglyceride levels were determined by 
colorimetric methods, and high-density lipoprotein (HDL) cholesterol 
level assayed in the supernatant after polyethylene glycol precipitation. 
Levels of low-density lipoprotein (LDL) cholesterol were calculated by 
the Friedewald formula if the total triglyceride level was < 4.5 mmol/L.  
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Selection of study subjects  
 Inclusion criteria-   Patients with Type 1 Diabetes Mellitus  
 Exclusion criteria-  
1. Patients on treatment with lipid lowering drugs  
2. Pregnant patients  
3. Patients with other endocrine disturbances.  
4. Patients on drugs which can cause hyperglycemia, hypertension 
or hyperlipidemia. 
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Definitions: 
Type 1 Diabetes Mellitus- 
A form of diabetes mellitus in which the insulin- secreting capacity 
of pancreatic ß-cells is completely destroyed. 
In this study we have identified patients in whom onset of diabetes 
occurred before the age of 25 yrs and who became insulin dependent 
within one year of starting treatment.  
Diabetes Mellitus is characterized by recurrent or persistent 
hyperglycemia and is diagnosed by demonstrating any one of the 
following: 
 Fasting Plasma Glucose at or above 126 mg/dl 
 Random Plasma glucose at or above 200mg/dl plus symptoms of 
diabetes. 
Poor glycemic control 
  Was defined as the average of fasting blood sugar done at monthly 
intervals over one year of more than 140 mg/dl33. 
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Metabolic syndrome: 
According to the NCEP ATP III criteria, the metabolic syndrome is  
presence of 3 or more of: 
1. Central obesity as measured by waist circumference:  
           Men >40 inches (102 cms):            Women >35 inches(88 cms) 
2. Fasting blood triglycerides > 150 mg/dL 
3. Blood HDL cholesterol: Men<40 mg/dL: Women<50 mg/dL 
4. Blood pressure > 130/85 mmHg or documented use of 
antihypertensives. 
5. Fasting glucose >110 mg/dL 
 
Physical activity: A questionnaire on the daily physical activity level 
was used to classify people into heavy physical work, moderate physical 
activity and sedentary lifestyle. 
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Hypothesis: 
Type 1 diabetes mellitus (DM1) is due to the autoimmune 
destruction of beta cells within the pancreatic islets. In contrast to DM1, 
which has an autoimmune cause, the underlying defect that causes type 2 
diabetes (DM2) is insulin resistance. Normally, insulin acts as a signal to 
promote glucose uptake and metabolism in the muscle. However, the 
muscle of people with DM2 is resistant to this signal. Therefore the 
insulin-secreting pancreatic beta cells have to increase production to 
increase the insulin signal to the defective muscle. As the patient's insulin 
resistance becomes more severe over time, the pancreatic beta cells are 
eventually exhausted and fail. At that point, blood glucose levels start to 
rise and type 2 diabetes can be diagnosed. People with type 2 diabetes 
have an underlying genetic predisposition towards insulin resistance. 
There are 3 factors that cause insulin resistance to worsen and lead to 
DM2: aging, gaining weight, and becoming more sedentary.  
It is quite possible to have a patient who develops DM1 due to 
autoimmune destruction of beta cells who also has the genetic 
predisposition for insulin resistance. Therefore, if this patient gains 
weight and becomes more sedentary, insulin resistance and features of the 
dysmetabolic syndrome could occur. As DM1 patients with the genetic 
predisposition for insulin resistance gain weight and become more 
 32
sedentary, they could require higher doses of insulin. Furthermore, they 
may also have increased cardiovascular risk. People with insulin 
resistance have been shown to have lower protective HDL cholesterol 
levels, higher plasminogen activator inhibitor 1 (PAI-1) levels and higher 
C-reactive protein (CRP) levels (indicating vascular inflammation). Thus, 
treating the insulin resistance could have theoretical potential for 
lowering insulin requirements and could possibly lessen cardiac risk in 
DM1 in patients with features of the dysmetabolic syndrome. 
Type 1 and type 2 diabetes frequently co-occur in the same 
families, suggesting common genetic susceptibility. In populations with a 
high prevalence of type 1 diabetes, like in Finland, a large proportion of 
patients with type 2 diabetes should have inherited susceptibility genes 
for both types of diabetes. Also, the lifestyle changes leading to the type 2 
diabetes epidemic around the world may have an impact on the clinical 
picture of type 1 diabetes in the subjects at risk for type 2 diabetes as 
well. According to the "accelerator hypothesis," there are two accelerators 
precipitating disease in all types of diabetes: the intrinsically high rate of 
ß-cell apoptosis and insulin resistance resulting from weight gain and 
physical inactivity. 
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RESULTS 
 34
In our study group of 100 patients 21 patients were found to have 
Metabolic Syndrome as defined by NCEP ATP III criteria.  
 
21
79
MS
Non MS
Prevalence of MS
 
Figure 2 Prevalence of Metabolic Syndrome in the study group 
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Age : 
The mean age of the patients in the study group was 28.0 yrs 
±1.99.The mean age of the patients with Metabolic syndrome is 35.29 
years (±12.44) and the mean age for those without is 26.65 years (±8.70). 
On using the Student t – test we found a statistically significant 
association between age of the patient and occurrence of metabolic 
syndrome. 
 
Table 2 Age distribution among the study group 
 
TYPE 
AGE  
P VALUE MEAN SD 
MS 35.29 12.44  
<0.001 Non MS 26.65 8.70 
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Figure 3 Error bar showing confidence interval for age distribution 
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Figure 4 Age Distribution among Study Group 
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Sex Distributon: 
58% of the cases in the study group were male and 42% were 
female. Among the patients with Metabolic Syndrome 47.6% were male 
and 52.4% were female. On comparing this with the gender prevalence 
among those without Metabolic Syndrome no statistically significant 
association was found between sex of the patient and Metabolic 
syndrome. 
Table 3 Sex distribution among the subgroups 
79 (79%)
21 ( 21%)
Total 
31 (39.2%)48 (60.8%)Non MS
11( 52.4%)10 (47.6%)MS
FemalesMales
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
MS No MS
Male
Female
 
Figure 5 Sex Distribution 
 38
Duration of Diabetes: 
The mean duration of diabetes among patients with Metabolic 
syndrome was found to be 11.81 yrs (± 6.98) and the mean for those 
without metabolic syndrome was 6.89 yrs (±5.86). On statistically 
analyzing the data with Chi square test statistical significance was 
achieved, showing an association between increasing duration of diabetes 
and presence of Metabolic Syndrome. 
Table 4 Duration of diabetes among the subgroups 
 Type No. Mean Std. Deviation P value 
Duration MS 21 11.81 6.976  
<0.001 Non-MS 79 6.89 5.855 
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Figure 7 Duration of Diabetes among Study Group 
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Insulin requirement: 
The average insulin requirement per day among patients with 
Metabolic syndrome is 65.90 units (±26.15) and that for patients without 
metabolic syndrome is 59.19 units (±24.08). No significant correlation 
was found between insulin requirement and occurrence of metabolic 
syndrome. 
 
Table 5 Insulin requirement per day among the sub groups 
    Type N Mean Std. Deviation P value 
 
Insulin 
(U/day) 
 
MS 
 
21 
 
65.90 
 
26.149 
 
0.267 
 
Non-MS 
 
79 
 
59.19 
 
24.075 
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Lifestyle: 
Among the diabetic patients with metabolic syndrome the 
distribution of lifestyle pattern into heavy physical work, moderate 
physical activity and sedentary lifestyle was 9.5%, 38.1% and 52.4% 
respectively. Among those without metabolic syndrome 12.7% did heavy 
physical work, 60.8% had moderate physical activity and 26.6% led a 
sedentary life. 
 
Figure 8 Shows the distribution of patients into three groups based 
on lifestyle 
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Glycemic control: 
32(32%) of the total 100 diabetic patients had poor glycemic 
control., and 68 (68%) had good glycemic control. 7 (33.3%) of the 21 
patients with Metabolic syndrome has poor glycemic control while 24 
(30.4%) of the 79 patients without metabolic syndrome had poor 
glycemic control.  
No significant association was found between glycemic control and 
occurrence of metabolic syndrome. 
 
Table 6 Glycemic control among the sub groups. 
 
  
Type 
 
N 
 
Poor 
 
Good 
 
P value 
 
Glycemic 
Control 
 
MS 
21 7 (33.3%) 14 (6.7%)  
0.795 
 
Non-MS 
79 24 (30.4%) 55 (69.6%) 
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Figure 9 Distribution of glycemic control among study group 
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Components of Metabolic Syndrome: 
The various components of metabolic syndrome were distributed in 
the following way among patients with Metabolic syndrome. 
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Figure 10 Components of Metabolic Syndrome 
 
The most common component was low HDL values which was 
found in 95.2% of patients with metabolic syndrome and the least 
common was Hypertension which was found in 42.9% of patients. 
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Dyslipidemia 
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Figure 11 Dyslipidemias among Type 1 Diabetes 
 
 
15% of type 1 diabetics had both hypertriglyceridemia and low 
HDL. But the most common dyslipidemia was low HDL alone, which 
was found in 28% of the patients. Hypertriglyceridemia in isolation was 
documented in 21% of the patients. Among the patients with Metabolic 
Syndrome also low HDL was the most commonly found association. 
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Hypertension 
11 patients among the cohort of hundred were found to have 
hypertension. 10 of them  had Metabolic Syndrome. 
 
 
Figure 12 Prevalence of Hypertension among Type 1 Diabetes 
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Central Obesity: 
 
16% of the type 2 Diabetics had central obesity. 10 among this 16 
had metabolic Syndrome. 
 
 
16
84
Central
Obesity
No
central
obesity
Central Obesity among patients with Diabetes
 
Figure 13 Central Obesity among Patients with Diabetes 
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DISCUSSION 
 49
Insulin resistance (IR) plays a larger role in the type 1 diabetes 
mellitus (T1DM) disease process than commonly recognized.26 
Overweight and physical inactivity have increased steadily for the last 20-
30 years in children and adolescents in many populations, concurrently 
with a rising incidence of T1DM. The role of IR in T1DM has only 
recently been gaining acceptance.26 It is now suspected that insulin 
resistance occurs in those with type 1 diabetes in the same way as it does 
in those with type 2, essentially giving these individuals double diabetes 
and greatly increasing their risk of heart disease.27 
We have used the NCEP ATP III criteria for diagnosis for 
metabolic syndrome in this study as it have been widely accepted and is 
relatively simple to apply28. The prevalence of metabolic syndrome in 
this study is 21%. Given below is a comparison of the prevalence 
obtained in various international studies. No Indian data regarding the 
same has been found during literature search. 
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Table 7 Comparing prevalence of MS among various studies 
 
Study  
 
Type 1 DM  
 
Prevalence of  
Met Syndrome 
FinnDiane study29 2415 40% 
DCCT27 1337 25.2% 
Johan Wadén, Lena M. Thorn, et al  
Finn Diane study30 
1028 39% 
Metascreen writing committee 
Italy31 
628 39.3% 
Pittsburg Epidemiology of Diabetic 
Complications study32 
514 21% 
F Al-Saraj, JH McDermott et al 
Endocrine Abstracts 200424 
32 16% 
Present study 100 21% 
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Figure 14 : Comparative analysis of prevalence of MS 
 
There is considerable variation in the prevalence ranging from 16% 
to 40% which can be explained by the fact that each study has used an 
entirely different race as the study group. Though most of the above 
studies have also used NCEP ATP III criteria, the prevalence was 
compared with other criteria like IDF and WHO. Another main reason for 
the difference would be the study design. The cross sectional studies 
show prevalence similar to that obtained in our study but prospective 
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studies show a higher prevalence probably due to the continuously 
increasing weight gain. 
Age distribution:  
The overall average age of the study group was 28.5 yrs and that 
for those with MS and without MS was 35.33 and 25.30 yrs. When 
analysed statistically it was found advancing age of the patient was 
found to correlate positively with incidence of MS (P<0.001). This can 
be explained by the fact that abdominal obesity and hypertension increase 
with age. Prolonged insulin therapy and sedentary lifestyle are what 
contribute to the progressive weight gain. The FinnDiane study also 
showed a similar increase in MS with age.29 
Table 8 Showing age distribution in various studies 
Study Number  Mean 
age 
FinnDiane study29 2415 37.0 yrs 
DCCT27 1337 26.5yrs 
Metascreen writing committee 
Italy31 
628 33.3yrs 
Current study 100 35.33 yrs 
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Sex Distribution 
The overall sex distribution was 57% males and 43% females, 
while in the cohort with MS the distribution was 47.6% males and 53.4% 
females. So the prevalence of MS among women was 23.40% and among 
men was 18.86%. No significant correlation was found between sex of 
the patient and occurrence of Metabolic syndrome. (P=0.278). The 
DCCT trial showed a higher incidence of MS among men, though it 
could not be explained with the current knowledge.27 
Duration of Diabetes: 
 Mean duration of diabetes among the patients with MS was 
11.81 yrs and for those without MS was 6.89 yrs.  The incidence of 
metabolic syndrome was found to increase with increasing duration of 
diabetes (P<0.001). 
Lifestyle. 
Patients were classified into sedentary, moderate activity and heavy 
physical labour based on a detailed questionnaire recording their average 
physical activity at work and during leisure. They were classified as 
follows : sedentary (LTPA <10 MET h/week, moderately active (LTPA 
10–40 MET h/week), and active (LTPA >40 MET h/week). It was seen 
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that the prevalence of metabolic syndrome among patients with active 
lifestyle, moderate activity and sedentary lifestyle was 9.5%, 38.1% and 
52.4%. on analyzing the data with Chi square test it was shown that the 
prevalence of metabolic syndrome increased with decreasing physical 
activity. Johan Wadén, , Lena M. Thorn, Carol Forsblom et al conducted 
a study using data from FinnDiane group and they demonstrated a similar 
correlation. Among patients reporting LTPA of low, moderate, or high 
intensity, 39.0, 28.3, and 23.2% (age-adjusted P = 0.008) had metabolic 
syndrome, respectively.30 
 One of the reasons for Type 1 DM to develop MS is thus proposed 
to be decreased physical activity leading to obesity which in turn leads to 
insulin resistance. 
Glycemic control and insulin requirement: 
Since HbA1c was not available in our setup we have used a 
surrogate marker to measure glycemic control in the form of average of 
monthly Fasting blood sugar values over one year.33 In our study no 
correlation was found between glycemic control and MS. 66.7% of 
patients with MS had a good glycemic control. The FinnDiane study 
actually showed increasing incidence of Metabolic syndrome with 
worsening glycemic control.29 
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The reason for our study failing to demonstrate a correlation is 
probably that we have used a poor surrogate marker for glycemic control 
when compared to the other studies. But this could not be avoided due to 
financial constraints. A relatively small number of patients have been 
studied this could be another reason for the lack of statistical significance. 
Average Insulin requirement per day among patients with MS was 
65.90 units while that for those without MS was 59.19 Units. Though the 
insulin requirement was higher in the MS group a statistical significance 
could not be demonstrated. An increase in insulin requirement is actually 
considered a clinical clue for the onset of metabolic syndrome. 
Components of Metabolic Syndrome 
Dyslipidemias were found to be the most common component and 
hypertension was the least common. The IDF criteria use abdominal 
obesity as a mandatory criteria. But  high Waist hip ratio (WHR) was 
found only in 47.6% of our study group. The DCCT study quoted 
below used the IDF criteria so all the patients with MS had a high WHR. 
Even otherwise abdominal obesity is not as high as is expected from most 
studies. This can be explained by the fact that Asian patients with Type 1 
DM are found to have a lean body habitus compared to the Caucasian 
counterparts. So central obesity can be considered an indicator of 
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metabolic syndrome in type 1 diabetics but is not found as commonly as 
it is in type 2 DM. 
Table 9 Components of metabolic syndrome 
 Low 
HDL 
High 
TG 
High BP High 
WHR
Present study 95.2% 71.4% 42.4% 47.6
% 
F Al-Saraj, JH McDermott et al 
 Endocrine Abstracts 200424 
56.0% 52.7% 86.8% 79.1
% 
DCCT26 84.87% 16.15% 9.62% 100%
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Future research: 
 Since sparse data is available on demographic and epidemiological 
information of metabolic syndrome in Type 1 DM this can be considered 
an area for future research. A prospective study on the impact of MS on 
the complications of DM in our setup will help in reducing the morbidity 
and mortality associated with this disease.  Population of Metabolic 
syndrome among type 1 DM and type 2 DM can be compared to see if 
the features between the two ends of the spectrum are similar. 
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Summary 
Aims:  
The aim of the study is to assess the prevalence of metabolic syndrome 
among Type 1 diabetics and assess its risk factors. 
Methodology:  
Consecutive 100 patients with Type 1 diabetes registered in the 
Diabetology Department were screened for height, weight, BMI, waist 
and hip circumference, blood pressure and lipid profile. Metabolic 
syndrome was considered as per the NCEP-ATP III criteria. Glycemic 
control was defined based on the average of fasting blood sugar over one 
year. The data was analysed statistically.  
Results:  
The overall prevalence was 21%, among males it was 17.2% and 26.2% 
in women. The criteria of HDL cholesterol, triglyceride, waist 
circumference and hypertension were present in 95.2%, 71.4%, 47.6%, 
and 42.9% of subjects respectively. The occurrence of MS was 
significantly correlated with advancing age (p<0.001), duration of 
diabetes (p<0.001), poor glycemic control (0.0023) and sedentary 
lifestyle. No correlation was found between gender and insulin dosage of 
the patient and metabolic syndrome.  
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CONCLUSIONS 
1. Metabolic syndrome is more common in type 1 Diabetes than 
commonly recognised. The prevalence of metabolic syndrome among 
Type 1 Diabetes patients is found to be 21%.  
2. The prevalence of metabolic syndrome is seen to increase with 
increasing age and increasing duration of diabetes. 
3. Sedentary lifestyle has been shown to be an important risk factor for 
development of metabolic syndrome. So it is proposed that the 
lifestyle changes leading to obesity are the underlying basis for the 
development of Insulin resistance. 
4. No significant association exists between glycemic control or insulin 
requirement and presence of metabolic syndrome. 
5. Dyslipidemias have been found to be the most commonly found 
component of Metabolic syndrome in the study group. Central obesity 
and hypertension are seen to be less prevalent when compared to other 
studies. 
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PROFORMA: 
 
Name: 
 
Age: 
Sex: 
Duration of diabetes: 
Glycemic control: 
Avg Fasting glucose of one year: 
Insulin requirement per day: 
Lifestyle: 
Waist circumference: 
Waist Hip Ratio:                                              HDL(mg/dl): 
TG(mg/dl):                                                       BP(mm hg): 
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MASTER CHART 
Sl.No. TYPE AGE(YRS) SEX DURATION OF DIABETES(YRS) 
GLYCEMIC 
CONTROL 
INSLIN 
REQUIREMENT 
(U/DAY) 
LIFESTYLE CENTRAL OBESITY HDL(mg/Dl) TG(mg/dl) 
SYS 
BP 
(mm 
hg) 
DIAST 
BP(mm 
hg) 
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1 Met Syn 33 F 5 POOR 68 SEDENTARY PRESENT 32 239 130 78 
2 Met Syn 30 F 10 POOR 72 MODERATE PRESENT 38 207 124 80 
3 Met Syn 44 M 28 GOOD 62 SEDENTARY ABSENT 40 190 130 72 
4 Met Syn 33 F 4 GOOD 60 SEDENTARY PRESENT 39 228 130 74 
5 Met Syn 23 M 7 GOOD 40 MODERATE ABSENT 30 217 124 74 
6 Met Syn 45 F 12 POOR 124 SEDENTARY PRESENT 34 206 124 76 
7 Met Syn 39 F 7 POOR 141 SEDENTARY PRESENT 31 127 122 74 
8 Met Syn 41 F 11 GOOD 63 SEDENTARY PRESENT 56 163 120 76 
9 Met Syn 43 F 10 GOOD 55 MODERATE PRESENT 35 98 110 80 
10 Met Syn 18 M 7 GOOD 56 SEDENTARY ABSENT 32 185 113 80 
11 Met Syn 22 F 7 GOOD 64 SEDENTARY PRESENT 30 184 110 70 
12 Met Syn 15 F 12 GOOD 60 SEDENTARY PRESENT 32 197 110 80 
13 Met Syn 20 M 12 GOOD 32 HEAVY ABSENT 36 140 140 90 
14 Met Syn 20 M 8 POOR 72 MODERATE ABSENT 32 126 148 100 
15 Met Syn 48 M 31 GOOD 48 MODERATE ABSENT 34 96 160 100 
16 Met Syn 38 F 12 GOOD 51 SEDENTARY PRESENT 32 102 150 90 
17 Met Syn 40 M 10 GOOD 40 HEAVY ABSENT 33 175 140 90 
Sl.No. TYPE AGE(YRS) SEX DURATION OF DIABETES(YRS) 
GLYCEMIC 
CONTROL 
INSLIN 
REQUIREMENT 
(U/DAY) 
LIFESTYLE CENTRAL OBESITY HDL(mg/Dl) TG(mg/dl) 
SYS 
BP 
(mm 
hg) 
DIAST 
BP(mm 
hg) 
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18 Met Syn 45 F 12 POOR 48 MODERATE ABSENT 32 172 140 88 
19 Met Syn 36 M 7 GOOD 64 MODERATE ABSENT 35 187 150 90 
20 Met Syn 42 M 15 GOOD 68 MODERATE ABSENT 35 198 140 90 
21 Met Syn 66 M 21 POOR 96 SEDENTARY ABSENT 37 194 160 110 
22 No MS 12 M 3 POOR 52 MODERATE ABSENT 52 136 130 70 
23 No MS 25 F 10 GOOD 44 MODERATE ABSENT 66 98 126 72 
24 NO MS 16 F 4 GOOD 56 MODERATE ABSENT 58 101 110 74 
25 NO MS 18 F 5 GOOD 48 MODERATE ABSENT 59 128 112 78 
26 NO MS 50 M 16 POOR 80 SEDENTARY PRESENT 74 130 120 78 
27 NO MS 15 M 3 GOOD 42 SEDENTARY ABSENT 37 95 130 80 
28 NO MS 27 M 20 POOR 60 MODERATE ABSENT 74 111 120 74 
29 NO MS 21 M 4 GOOD 40 MODERATE ABSENT 68 128 112 74 
30 NO MS 18 F 12 GOOD 72 MODERATE ABSENT 50 141 130 78 
31 NO MS 45 F 21 POOR 68 HEAVY PRESENT 64 118 120 70 
32 NO MS 20 M 5 POOR 75 SEDENTARY ABSENT 75 131 132 70 
33 NO MS 28 M 12 GOOD 64 SEDENTARY ABSENT 54 97 132 76 
34 NO MS 17 F 6 POOR 68 SEDENTARY ABSENT 75 242 128 78 
Sl.No. TYPE AGE(YRS) SEX DURATION OF DIABETES(YRS) 
GLYCEMIC 
CONTROL 
INSLIN 
REQUIREMENT 
(U/DAY) 
LIFESTYLE CENTRAL OBESITY HDL(mg/Dl) TG(mg/dl) 
SYS 
BP 
(mm 
hg) 
DIAST 
BP(mm 
hg) 
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35 NO MS 48 M 1 GOOD 36 SEDENTARY PRESENT 36 108 130 70 
36 NO MS 45 M 22 GOOD 46 MODERATE ABSENT 55 99 130 72 
37 NO MS 26 M 5 GOOD 80 MODERATE ABSENT 62 127 120 78 
38 NO MS 31 M 5 GOOD 60 MODERATE ABSENT 65 114 110 78 
39 NO MS 22 M 4 GOOD 23 MODERATE ABSENT 59 117 120 72 
40 NO MS 18 F 6 GOOD 42 MODERATE ABSENT 76 104 120 70 
41 NO MS 30 M 15 POOR 86 SEDENTARY ABSENT 65 131 130 70 
42 NO MS 33 M 8 POOR 35 MODERATE ABSENT 65 97 130 79 
43 NO MS 27 F 7 GOOD 60 MODERATE ABSENT 61 146 130 80 
44 NO MS 30 M 19 POOR 86 MODERATE ABSENT 68 147 120 80 
45 NO MS 19 F 3 GOOD 60 MODERATE ABSENT 77 136 110 80 
46 NO MS 48 M 2 POOR 120 SEDENTARY ABSENT 53 138 110 80 
47 NO MS 29 M 5 POOR 70 MODERATE ABSENT 70 146 110 78 
48 NO MS 33 F 5 POOR 68 MODERATE ABSENT 57 113 128 78 
49 NO MS 32 M 3 GOOD 60 MODERATE ABSENT 54 113 128 78 
50 NO MS 19 F 4 GOOD 52 MODERATE ABSENT 57 90 128 76 
51 NO MS 26 M 3 GOOD 52 SEDENTARY ABSENT 76 98 128 70 
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52 NO MS 23 F 3 GOOD 20 SEDENTARY ABSENT 79 118 128 80 
53 NO MS 28 M 3 POOR 90 HEAVY ABSENT 58 148 110 80 
54 NO MS 41 M 3 GOOD 60 MODERATE ABSENT 74 111 112 80 
55 NO MS 34 M 7 GOOD 32 MODERATE ABSENT 75 94 126 74 
56 NO MS 27 F 2 GOOD 32 MODERATE ABSENT 63 144 126 70 
57 NO MS 29 F 10 GOOD 28 MODERATE ABSENT 73 175 126 78 
58 NO MS 16 F 1 POOR 58 MODERATE ABSENT 69 96 112 80 
59 NO MS 23 M 5 GOOD 50 MODERATE ABSENT 61 144 110 80 
60 NO MS 39 M 23 GOOD 40 MODERATE ABSENT 51 116 130 74 
61 NO MS 20 F 2 POOR 48 MODERATE ABSENT 56 153 110 72 
62 NO MS 21 M 2 GOOD 24 MODERATE ABSENT 76 90 124 72 
63 NO MS 14 F 6 GOOD 60 MODERATE ABSENT 69 127 124 70 
64 NO MS 24 M 2 GOOD 42 SEDENTARY ABSENT 54 139 124 76 
65 NO MS 38 M 6 POOR 92 SEDENTARY PRESENT 50 148 122 80 
66 NO MS 21 M 8 GOOD 60 HEAVY ABSENT 30 123 122 74 
67 NO MS 25 M 1 GOOD 64 MODERATE ABSENT 74 115 122 74 
68 NO MS 22 F 1 GOOD 71 SEDENTARY ABSENT 77 165 122 82 
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69 NO MS 31 F 18 GOOD 48 MODERATE ABSENT 61 136 120 72 
70 NO MS 29 F 16 GOOD 27 MODERATE ABSENT 50 148 120 74 
71 NO MS 29 M 16 GOOD 97 MODERATE ABSENT 39 103 120 80 
72 NO MS 18 M 2 POOR 72 MODERATE ABSENT 66 147 118 70 
73 NO MS 26 M 4 GOOD 36 SEDENTARY ABSENT 53 150 118 80 
74 NO MS 33 F 7 GOOD 68 HEAVY ABSENT 77 100 116 72 
75 NO MS 33 F 10 GOOD 68 HEAVY ABSENT 72 138 116 80 
76 NO MS 16 M 2 GOOD 116 MODERATE ABSENT 63 97 116 70 
77 NO MS 29 M 6 GOOD 56 HEAVY ABSENT 52 125 110 74 
78 NO MS 26 M 3 POOR 60 MODERATE ABSENT 58 108 110 80 
79 NO MS 24 M 10 GOOD 18 MODERATE ABSENT 66 130 116 74 
80 NO MS 30 M 3 GOOD 21 MODERATE ABSENT 67 127 130 80 
81 NO MS 17 F 6 GOOD 60 MODERATE ABSENT 71 100 126 80 
82 NO MS 19 F 1 POOR 72 MODERATE ABSENT 71 147 114 70 
83 NO MS 31 M 5 GOOD 40 MODERATE ABSENT 51 105 114 80 
84 NO MS 21 F 5 GOOD 72 MODERATE ABSENT 65 131 114 76 
85 NO MS 50 M 23 GOOD 62 SEDENTARY PRESENT 79 130 114 80 
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86 NO MS 28 M 1 GOOD 44 HEAVY ABSENT 68 134 130 80 
87 NO MS 23 F 5 GOOD 42 MODERATE ABSENT 62 127 130 70 
88 NO MS 21 M 1 GOOD 60 SEDENTARY ABSENT 65 99 114 70 
89 NO MS 24 M 8 POOR 42 HEAVY ABSENT 51 126 112 80 
90 NO MS 16 F 6 GOOD 110 HEAVY ABSENT 54 135 112 70 
91 NO MS 39 F 7 POOR 141 MODERATE ABSENT 53 148 124 76 
92 NO MS 27 F 13 GOOD 72 SEDENTARY ABSENT 76 146 126 78 
93 NO MS 18 F 4 POOR 48 MODERATE ABSENT 62 119 130 72 
94 NO MS 22 M 4 GOOD 74 MODERATE ABSENT 78 148 120 70 
95 NO MS 19 M 17 POOR 117 SEDENTARY ABSENT 51 161 120 70 
96 NO MS 25 M 6 POOR 80 HEAVY ABSENT 39 106 110 70 
97 NO MS 25 M 2 GOOD 32 MODERATE ABSENT 40 99 110 70 
98 NO MS 29 M 3 GOOD 52 SEDENTARY ABSENT 37 126 110 80 
99 NO MS 21 F 1 GOOD 47 SEDENTARY ABSENT 53 132 110 80 
100 NO MS 33 M 6 GOOD 46 SEDENTARY ABSENT 70 145 148 96 
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